Top

Published in:

Open Access 01-12-2016 | Erratum

Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

Authors: Christoph Kampmann, Amandine Perrin, Michael Beck

Published in: Orphanet Journal of Rare Diseases | Issue 1/2016

Excerpt

Following the publication of our article “Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment” by Kampmann et al. [1] we have become aware that the dose of agalsidase alfa was not reported. …

Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:125.CrossRefPubMedPubMedCentral

Title: Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
Authors: Christoph Kampmann
Amandine Perrin
Michael Beck
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2016
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-016-0482-3

At a glance: The STEP trials

Springer Medicine

Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes

ROHHAD syndrome and evolution of sleep disordered breathing

Invasive meningococcal disease in three siblings with hereditary deficiency of the 8th component of complement: evidence for the importance of an early diagnosis

Arrhythmogenic cardiomyopathy

POEMS syndrome and calciphylaxis: an unrecognized cause of abnormal small vessel calcification

Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995–2012